The compounds are analogs of Novartis’ Ritalin, used for treatment of ADHD and designed specifically to take effect slowly but last longer, thus reducing their potential for abuse and a patient’s required daily dosage.
The research will be conducted under the supervision of Dr Mark Froimowitz, a researcher at the Boston-based college, who recently licensed the compounds to DNAPrint Genomics.
“These Ritalin-like compounds present an ideal opportunity for our goal to develop products for personalized medicine,” stated DNAPrint chief medical officer Dr Hector Gomez. “DNAPrint’s capabilities in genomics and the College’s expertise in pharmaceuticals represent a powerful synergy in the field of theranostic drug research.”